Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD

• Status: Completed
• Trial end date: 2019-11-08
• Target enrollment: 0
• Participant gender: All

Summary

Parenteral nutrition-associated cholestasis (PNAC) and liver disease (PNALD) are associated with significant morbidity and mortality in neonates and is felt to be exacerbated by soybean-based lipid emulsions. Much research is currently being directed at identifying ways to reduce this risk. Reduction of the dose of soybean-based lipid given as a component of parenteral nutrition is one possible strategy. In this study we will compare standard dosing of soybean-based lipid (up to 3/kg/day) with a minimized dose (1 g/kg/day) and evaluate for the development of cholestasis and adequate growth between the two groups. Longterm followup will include an assessment of neurodevelopmental outcomes at 12 and 24 months of age.

Funding source - FDA OOPD

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Michigan
• Collaborators: Primary Children's Hospital; Seattle Children's Hospital; University of Colorado, Denver; University of Florida
• Treatments: Soybean oil, phospholipid emulsion

Criteria

Inclusion Criteria:

• neonates and infants who are at least 28 weeks corrected gestational age at the time of enrollment who are parenteral nutrition (PN) naive

• current direct bilirubin <2 mg/dL

• any of the following conditions:

• meconium ileus and peritonitis

• gastroschisis

• omphalocele >4cm or with liver herniated outside of the abdominal cavity

• necrotizing enterocolitis requiring surgical intervention

• volvulus

• intestinal atresia with >50% bowel loss

Exclusion Criteria:

• weight <1 kg

• metabolic pathway defect which is associated with liver dysfunction in the neonatal period, including: hereditary fructose intolerance, galactosemia due to transferase deficiency and neonatal tyrosinemia, and/or disorder of lipid metabolism

• hepatic insufficiency as documented by either a biopsy with cirrhosis and/or marked aberration in synthetic function

• renal failure

• primary or secondary liver disease, regardless of liver function (includes hepatitis)

• use of extracorporeal membrane oxygenation (ECMO)

• suspected congenital obstruction of the hepatobiliary tree

• documented active infection which may be communicable, including infections hepatitis or HIV

• previous receipt of choleretic agents

• currently receiving phenobarbital or other barbiturates

• history of PNAC

• direct bilirubin >=2 mg/dL at time of enrollment

• congenital or acquired anomaly which will require major cardiovascular surgery

• major congenital or chromosomal anomaly

• hypoxic ischemic encephalopathy

• congenital defect of the brain

• major seizure disorder